Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas cut its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVAFree Report) by 18.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 51,598 shares of the biotechnology company’s stock after selling 11,691 shares during the quarter. Teacher Retirement System of Texas’ holdings in Iovance Biotherapeutics were worth $419,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Iovance Biotherapeutics by 8.6% during the third quarter. Vanguard Group Inc. now owns 22,143,470 shares of the biotechnology company’s stock worth $100,753,000 after purchasing an additional 1,748,082 shares during the last quarter. Artisan Partners Limited Partnership raised its holdings in Iovance Biotherapeutics by 13.8% during the third quarter. Artisan Partners Limited Partnership now owns 5,036,479 shares of the biotechnology company’s stock worth $22,916,000 after purchasing an additional 609,738 shares during the last quarter. MPM Bioimpact LLC raised its holdings in Iovance Biotherapeutics by 11.4% during the third quarter. MPM Bioimpact LLC now owns 3,287,397 shares of the biotechnology company’s stock worth $14,958,000 after purchasing an additional 337,279 shares during the last quarter. Principal Financial Group Inc. raised its holdings in Iovance Biotherapeutics by 41.3% during the third quarter. Principal Financial Group Inc. now owns 2,643,155 shares of the biotechnology company’s stock worth $12,026,000 after purchasing an additional 772,905 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Iovance Biotherapeutics by 3.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,747,023 shares of the biotechnology company’s stock worth $14,203,000 after purchasing an additional 54,490 shares during the last quarter. 77.03% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on IOVA. StockNews.com raised Iovance Biotherapeutics to a “sell” rating in a research report on Friday, February 2nd. The Goldman Sachs Group raised their price target on Iovance Biotherapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th. HC Wainwright reissued a “buy” rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a research report on Friday. Piper Sandler raised their price target on Iovance Biotherapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Thursday, March 14th. Finally, Barclays raised their price target on Iovance Biotherapeutics from $18.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.64.

View Our Latest Stock Report on Iovance Biotherapeutics

Iovance Biotherapeutics Trading Down 2.4 %

IOVA stock opened at $10.01 on Tuesday. The stock has a 50-day moving average price of $12.49 and a two-hundred day moving average price of $10.39. Iovance Biotherapeutics, Inc. has a 12-month low of $3.21 and a 12-month high of $18.33. The company has a market cap of $2.80 billion, a PE ratio of -5.56 and a beta of 0.66.

Iovance Biotherapeutics (NASDAQ:IOVAGet Free Report) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.03. The firm had revenue of $0.72 million during the quarter, compared to the consensus estimate of $1.99 million. Iovance Biotherapeutics had a negative return on equity of 71.45% and a negative net margin of 23,615.70%. The firm’s quarterly revenue was up 71400.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.50) earnings per share. Equities analysts forecast that Iovance Biotherapeutics, Inc. will post -1.37 EPS for the current fiscal year.

Iovance Biotherapeutics Company Profile

(Free Report)

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.

See Also

Institutional Ownership by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.